IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
Relative valuation derived from Healthcare sector median benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Multiples adjusted for extreme outliers and non-recurring volatility.
Auditing capital efficiency...
Quality Profile Audit
Score: 50GRADE C+
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation.
Return on Equity
Profit generated per dollar of shareholder equity
29.3%
Sector: -42.5%
Dividend Analysis audit
No Dividend
This company does not currently pay a dividend.
Analyst Projections
Analyst Consensus
Unlock Valuation Tools
Sign up for free access to institutional-quality research tools.
Based on our 6-factor quantitative model, PRO DEX INC (PDEX) receives a "Hold" rating with a composite score of 41.7/100, ranked #713 out of 4446 stocks. Key factor scores: Quality 50/100, Value 47/100, Momentum 47/100. This is quantitative analysis only — not investment advice.
PRO DEX INC (PDEX) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does PRO DEX INC Do?
Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company was founded in 1978 and is headquartered in Irvine, California. PRO DEX INC (PDEX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Richard Lee van Kirk and employs approximately 140 people, headquartered in IRVINE, California. With a market capitalization of $157M, PDEX is one of the notable companies in the Healthcare sector.
PRO DEX INC (PDEX) Stock Rating — Hold (April 2026)
As of April 2026, PRO DEX INC receives a Hold rating with a composite score of 41.7/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.PDEX ranks #713 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, PRO DEX INC ranks #37 of 839 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
PDEX Stock Price and 52-Week Range
PRO DEX INC (PDEX) currently trades at $51.67. The 52-week high for PDEX is $70.26, which means the stock is currently trading -26.5% from its annual peak. The 52-week low is $23.47, putting the stock 120.2% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.
Is PDEX Overvalued or Undervalued? — Valuation Analysis
PRO DEX INC (PDEX) carries a value factor score of 47/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 13.42x, compared to the Healthcare sector average of 23.29x — a discount of 42%. The price-to-book ratio stands at 3.93x, versus the sector average of 2.69x. The price-to-sales ratio is 2.29x, compared to 1.64x for the average Healthcare stock. On an enterprise value basis, PDEX trades at 12.87x EV/EBITDA, versus 6.36x for the sector.
Overall, PDEX's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
PRO DEX INC Profitability — ROE, Margins, and Quality Score
PRO DEX INC (PDEX) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 29.3%, compared to the Healthcare sector average of -42.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 19.6% versus the sector average of -33.1%.
On a margin basis, PRO DEX INC reports gross margins of 30.8%, compared to 71.3% for the sector. The operating margin is 17.8% (sector: -65.2%). Net profit margin stands at 17.0%, versus -54.1% for the average Healthcare stock. Revenue growth is running at 25.3% on a trailing basis, compared to 10.7% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
PDEX Debt, Balance Sheet, and Financial Health
PRO DEX INC has a debt-to-equity ratio of 50.0%, compared to the Healthcare sector average of 31.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 4.03x, indicating strong short-term liquidity. Total debt on the balance sheet is $10M. Cash and equivalents stand at $8M.
PDEX has a beta of 0.51, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for PRO DEX INC is 47/100, reflecting average volatility within the normal range for its sector.
PRO DEX INC Revenue and Earnings History — Quarterly Trend
In TTM 2026, PRO DEX INC reported revenue of $71M and earnings per share (EPS) of $0.67. Net income for the quarter was $12M. Gross margin was 30.8%. Operating income came in at $13M.
In Q2 2026, PRO DEX INC reported revenue of $19M and earnings per share (EPS) of $0.67. Net income for the quarter was $2M. Gross margin was 30.8%. Revenue grew 11.1% year-over-year compared to Q2 2025. Operating income came in at $3M.
In Q1 2026, PRO DEX INC reported revenue of $19M and earnings per share (EPS) of $1.43. Net income for the quarter was $5M. Gross margin was 29.0%. Revenue grew 24.4% year-over-year compared to Q1 2025. Operating income came in at $3M.
In FY 2025, PRO DEX INC reported revenue of $67M and earnings per share (EPS) of $2.73. Net income for the quarter was $155,000. Gross margin was 29.3%. Revenue grew 23.7% year-over-year compared to FY 2024. Operating income came in at $11M.
Over the past 8 quarters, PRO DEX INC has demonstrated a growth trajectory, with revenue expanding from $54M to $71M. Investors analyzing PDEX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
PDEX Dividend Yield and Income Analysis
PRO DEX INC (PDEX) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
PDEX Momentum and Technical Analysis Profile
PRO DEX INC (PDEX) has a momentum factor score of 47/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 6/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
PDEX vs Competitors — Healthcare Sector Ranking and Peer Comparison
Comparing PDEX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PDEX vs S&P 500 (SPY) comparison to assess how PRO DEX INC stacks up against the broader market across all factor dimensions.
PDEX Next Earnings Date
No upcoming earnings date has been announced for PRO DEX INC (PDEX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy PDEX? — Investment Thesis Summary
PRO DEX INC presents a balanced picture with arguments on both sides.
In summary, PRO DEX INC (PDEX) earns a Hold rating with a composite score of 41.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PDEX stock.
We'll email you when stocks you follow change their composite rating.
Institutional Research Dossier
PRO DEX INC (PDEX) Deep Dive Analysis
Published on March 24, 2026
Action RatingHold
Sections
Executive Summary
We maintain our Hold rating on Pro-Dex, Inc. (PDEX). While the company exhibits strong profitability metrics and impressive revenue growth compared to its sector, its significantly elevated valuation multiples, particularly its P/E ratio, temper our enthusiasm. The company's reliance on a limited number of key customers and the inherent risks associated with the medical device industry warrant a cautious approach, despite its operational strengths.
The primary takeaway is that PDEX, while demonstrating operational excellence and growth potential, is currently priced at a premium that may not be justified given its size, customer concentration, and the competitive landscape of the medical device sector. Investors should carefully weigh the company's growth prospects against its valuation and inherent risks before considering an investment.
Business Strategy & Overview
Pro-Dex, Inc. operates within the medical device industry, focusing on the design, development, and manufacturing of powered surgical instruments. Its core business revolves around supplying these instruments to medical device original equipment manufacturers (OEMs). The company's product portfolio includes autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers, primarily utilized in orthopedic, thoracic, and craniomaxillofacial surgical procedures. This specialization allows Pro-Dex to cater to specific needs within the surgical instrument market.
The company's revenue generation is primarily driven by contracts with medical device OEMs. Pro-Dex acts as a supplier, providing customized surgical instruments that are integrated into the OEMs' broader product offerings. In addition to manufacturing, Pro-Dex offers engineering, quality, and regulatory consulting services, further solidifying its relationships with its OEM partners. This integrated approach allows the company to capture additional value and build stickier customer relationships.
Pro-Dex also manufactures and sells rotary air motors to various industries, representing a diversification effort beyond the medical device sector. However, the medical device segment remains the primary driver of revenue and profitability. The company's strategic positioning involves focusing on specialized surgical instruments and providing value-added services to OEMs, allowing it to compete effectively in a niche market.
The medical device industry is characterized by stringent regulatory requirements, technological advancements, and intense competition. Pro-Dex must navigate these challenges by maintaining high-quality standards, complying with regulatory guidelines (such as those set by the FDA), and continuously innovating its product offerings. The company's success hinges on its ability to adapt to evolving market demands and maintain its competitive edge through technological innovation and customer service.
Execution Benchmarks audit
Revenue Growth
YOY expansion rate
25.3%
Sector: 10.7%
+136% VS SCTR
Economic Moat Analysis
Pro-Dex's economic moat can be classified as Narrow. The company's competitive advantage stems primarily from its specialized expertise in designing and manufacturing powered surgical instruments for medical device OEMs, coupled with its engineering and regulatory consulting services. This creates a degree of switching costs for its customers, as changing suppliers would require OEMs to invest time and resources in finding a new partner with comparable capabilities and regulatory knowledge.
The company's focus on specific surgical applications, such as orthopedic and craniomaxillofacial procedures, allows it to develop specialized knowledge and expertise that is difficult for generalist manufacturers to replicate. This specialization creates a barrier to entry for potential competitors and strengthens Pro-Dex's position within its niche market. Furthermore, the stringent regulatory requirements of the medical device industry act as a moat, as compliance requires significant investment and expertise.
However, the moat is not wide due to the relatively small size of Pro-Dex and its reliance on a limited number of key customers. This customer concentration exposes the company to the risk of losing a major contract, which could significantly impact its revenue and profitability. Additionally, the medical device industry is characterized by rapid technological advancements, which could erode Pro-Dex's competitive advantage if it fails to innovate and adapt to changing market demands.
While Pro-Dex possesses some intangible assets in the form of specialized knowledge and regulatory expertise, these assets are not as strong as those of larger, more established medical device companies with recognized brands and extensive patent portfolios. The company's cost advantages are also limited, as it operates in a relatively high-cost manufacturing environment. Therefore, while Pro-Dex has a defensible position within its niche market, its moat is not wide enough to provide a significant and sustainable competitive advantage over the long term.
Financial Health & Profitability
Pro-Dex exhibits a mixed financial profile. The company's revenue growth has been impressive, with a TTM revenue growth rate of 25.3% significantly exceeding the sector average of 10.7%. This indicates strong demand for its products and services. The quarterly financial history reveals a consistent upward trend in revenue, with recent quarters showing particularly strong performance. However, it is important to note that the company's revenue base is relatively small, making it more susceptible to fluctuations in demand.
Profitability metrics are also strong, with a TTM net margin of 17.0% and an operating margin of 17.8%, both significantly higher than the sector averages of -54.1% and -65.2%, respectively. The company's ROE of 29.3% is also impressive, indicating efficient use of equity capital. However, the gross margin of 30.8% is significantly lower than the sector average of 71.9%, suggesting that Pro-Dex may face challenges in controlling its cost of goods sold.
The balance sheet appears to be in good health, with a current ratio of 4.03 indicating strong liquidity. The company has $7.95 million in total cash and $10.47 million in total debt, resulting in a debt-to-equity ratio of 50.00, which is slightly higher than the sector average of 30.00. While the debt level is manageable, it is important to monitor the company's ability to service its debt obligations.
Free cash flow generation is a concern, with a TTM free cash flow of only $1.13 million. This relatively low level of free cash flow may limit the company's ability to invest in growth initiatives or return capital to shareholders. The absence of free cash flow data in the quarterly financial history makes it difficult to assess the trend in cash flow generation. Overall, Pro-Dex's financial health is characterized by strong revenue growth and profitability, but concerns remain regarding its gross margin and free cash flow generation.
Valuation Assessment
Pro-Dex's valuation is a significant concern. The company's P/E ratio of 69.5x is substantially higher than the sector average of 24.3x, indicating that the stock is trading at a significant premium to its peers. Similarly, its EV/EBITDA ratio of 11.5x is also higher than the sector average of 6.4x, further supporting the view that the stock is overvalued. This premium valuation may be justified if Pro-Dex were growing at a significantly faster rate than its peers and had a wider economic moat, but this is not the case.
Given the company's relatively small size and customer concentration, the current valuation appears to be excessive. While Pro-Dex has demonstrated strong revenue growth and profitability, these factors may already be priced into the stock. The high valuation multiples suggest that investors are expecting continued strong growth and profitability, which may not be sustainable in the long term. Any slowdown in revenue growth or decline in profitability could lead to a significant correction in the stock price.
A discounted cash flow (DCF) analysis would be necessary to determine the intrinsic value of the stock, but the lack of detailed financial projections makes this difficult. However, based on the available data, it is unlikely that the stock is significantly undervalued. The high valuation multiples suggest that the stock is either fairly valued or overvalued, depending on the assumptions used in the DCF analysis.
In summary, Pro-Dex's valuation is a major concern. The stock is trading at a significant premium to its peers, and this premium may not be justified given the company's size, customer concentration, and the competitive landscape of the medical device sector. Investors should exercise caution and carefully consider the risks associated with investing in an overvalued stock.
Risk & Uncertainty
Pro-Dex faces several specific risks that could negatively impact its business and financial performance. One of the most significant risks is customer concentration. The company relies on a limited number of key customers for a substantial portion of its revenue. The loss of a major customer could have a material adverse effect on the company's revenue and profitability. This risk is exacerbated by the fact that the medical device industry is highly competitive, and OEMs may choose to switch suppliers for various reasons, including price, quality, or technological innovation.
Another risk is the regulatory environment. The medical device industry is subject to stringent regulatory requirements, and Pro-Dex must comply with these regulations to market and sell its products. Changes in regulatory requirements or failure to comply with existing regulations could result in delays in product approvals, product recalls, or other enforcement actions, which could negatively impact the company's business. Furthermore, the company's reliance on third-party suppliers exposes it to the risk of supply chain disruptions, which could impact its ability to meet customer demand.
The company's relatively small size also poses a risk. Pro-Dex may lack the resources to compete effectively with larger, more established medical device companies. This could limit its ability to invest in research and development, marketing, and other growth initiatives. Additionally, the company's reliance on a limited number of products exposes it to the risk of technological obsolescence. If its products become outdated or are replaced by newer technologies, the company's revenue and profitability could decline.
Bulls Say / Bears Say
The Bull Case
BULL VIEWPro-Dex's strong revenue growth and high profitability metrics demonstrate its ability to capitalize on opportunities within the specialized surgical instrument market.
BULL VIEWThe company's focus on providing value-added services to medical device OEMs creates sticky customer relationships and a defensible niche within the competitive medical device industry.
BULL VIEWPro-Dex's solid balance sheet and strong liquidity position provide a financial cushion to support future growth initiatives and weather potential economic downturns.
The Bear Case
BEAR VIEWPro-Dex's sky-high valuation multiples, particularly its P/E ratio, suggest that the stock is significantly overvalued and vulnerable to a sharp correction.
BEAR VIEWThe company's reliance on a limited number of key customers exposes it to significant customer concentration risk, which could materially impact its revenue and profitability if a major contract is lost.
BEAR VIEWPro-Dex's relatively small size and limited free cash flow generation may constrain its ability to compete effectively with larger, more established medical device companies and invest in future growth.
About the Author
Marques Blank
Founder & Chief Investment Officer, Blank Capital
Marques brings 15 years of institutional finance and investing experience, having overseen financial planning for a $1.6B defense business unit. He developed the proprietary 6-factor quantitative model used to score PDEX and 4,400+ other equities.
PRO DEX INC exhibits a 36% valuation premium relative to institutional benchmarks. This represents a potential valuation overextension based on current multiples.
Return on Assets
Efficiency of asset utilization
19.6%
Sector: -33.1%
Gross Margin
Pricing power and cost efficiency
30.8%
Sector: 71.3%
Operating Margin
Core business profitability
17.8%
Sector: -65.2%
Net Margin
Bottom-line profitability
17.0%
Sector: -54.1%
Factor Methodology
The Quality factor evaluates the persistence and magnitude of cash flows. Companies with scores >70 exhibit superior competitive moats and financial resilience through economic cycles.
